Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $63.28 USD
Change Today +0.17 / 0.27%
Volume 845.6K
ALKS On Other Exchanges
As of 2:22 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Elliot W. Ehrich M.D.

Chief Medical Officer and Executive Vice President of Research and Development,Alkermes plc
AgeTotal Calculated CompensationThis person is connected to 22 board members in 2 different organizations across 3 different industries.

See Board Relationships
As of Fiscal Year 2014


Dr. Elliot W. Ehrich, M.D. serves as the Executive Vice President of Research and Development since February 2015 and Chief Medical Officer of Alkermes plc (also known as Alkermes Inc) since September 2011 and he served as Senior Vice President of Research & Development since May 22, 2007. Dr. Ehrich serves as a Member of Advisory Board of Epernicus LLC. He serves as a Member of Scientific Advisory Board of Aileron Therapeutics, Inc. Dr. Ehrich served as the Vice President ...

Read Full Background

Corporate Headquarters*

Connaught House
Dublin, Co. Dublin 4


Phone: 353 1 772 8000
Fax: --

Board Members Memberships*

There is no Board Members Memberships data available.


Unknown/Other Education
Stanford University
Princeton University
Columbia University College of Physicians & Surgeons in New York

Other Affiliations*

Annual Compensation*

Total Annual Compensation$468,120

Stock Options*

Restricted Stock Awards$707,400
All Other Compensation$13,100
Exercised Options104,650
Exercised Options Value$3,541,787
Exercisable Options178,527
Exercisable Options Value$7,162,283
Unexercisable Options210,250
Unexercisable Options Value$5,773,878
Total Value of Options$16,477,947
Total Number of Options493,427

Total Compensation*

Total Annual Cash Compensation$951,220
Total Short Term Compensation$468,120
Other Long Term Compensation$720,500
Total Calculated Compensation$3,188,761
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALKS:US $63.26 USD +0.15


David M. Stack Chairman, Chief Executive Officer and President
Pacira Pharmaceuticals, Inc.
James A. Schoeneck Chief Executive Officer, President and Director
DepoMed Inc.
George Frederick Wilkinson Chief Executive Officer, President and Director
Impax Laboratories Inc.
Bruce C. Cozadd Co-Founder, Executive Chairman and Chief Executive Officer
Jazz Pharmaceuticals Public Limited Company
Daniel J. Abdun-Nabi Chief Executive Officer, President, Director, Member of Strategic Operations Committee and Member of Pricing Committee
Emergent BioSolutions, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at